Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Ciclosporin (Verkazia®) is recommended as an option for use within NHS Wales for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents (until the age of 18). |
|||
|
|||
Medicine details |
|||
| Medicine name | ciclosporin (Verkazia®) | ||
| Formulation | 1 mg/ml eye drops | ||
| Reference number | 2908 | ||
| Indication | Treatment of severe vernal keratoconjunctivitis in children and adolescents from 4 to 18 years old |
||
| Company | Santen UK Ltd | ||
| BNF chapter | Eye | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0219 | ||
| NMG meeting date | 09/01/2019 | ||
| AWMSG meeting date | 13/02/2019 | ||
| Date of issue | 05/03/2019 | ||